Drug price hikes can damage company reputations: White House
- Top 10 News for 10/24 - 10/28: AT&T (T), Time Warner Make it Official; Margins Hamper Apple's Q4; Mergers Aplenty
- Wall St. falls as FBI to review more Clinton emails
- Clinton email problem resurfaces as FBI announces review
- ExxonMobil (XOM) Tops Q3 EPS by 5c; CapEx Light of Views
- Baker Hughes (BHI), General Electric (GE) in Partnership Talks, Not Merger Talks
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
WASHINGTON (Reuters) - The White House on Wednesday said pharmaceutical firms risked damaging their reputations with big price hikes, but it sidestepped commenting directly on Mylan NV's decision to raise the price of its severe allergy treatment drug EpiPen.
"I'm obviously not going to make specific comments to specifically second guess the pricing strategy ... of one private enterprise," White House spokesman Josh Earnest said at a news briefing.
"I will observe, however, that pharmaceutical companies that often try to portray themselves as the inventors of life-saving medication often do real damage to their reputation by being greedy and jacking up prices," he said.
(Reporting by Timothy Ahmann, editing by G Crosse)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mylan Launches First Generics of Benicar® and Benicar HCT® Tablets
- Mylan (MYL) Announces U.S. Launch of Generic Benicar Tabs
- Mylan (MYL) Gains on Generic Concerta Approval
Create E-mail Alert Related CategoriesGeneral News, Reuters
Related EntitiesRaising Prices
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!